202 related articles for article (PubMed ID: 18210116)
21. Asymptomatic primary rectal neuroendocrine carcinoma presented as a large pelvic mass.
Pittayanon R; Pantongrag-Brown L; Wisedopas N; Rerknimitr R
BMJ Case Rep; 2014 Feb; 2014():. PubMed ID: 24493107
[TBL] [Abstract][Full Text] [Related]
22. [A case of primary small cell neuroendocrine carcinoma of the liver].
Kim KJ; Yim HJ; Kim MJ; Choung RS; Yeon JE; Lee HS; Byun KS; Lee SW; Choi JH; Ryu HS; Lee CH; Hyun JH; Lee ES; Kim YS
Korean J Gastroenterol; 2006 Jul; 48(1):37-41. PubMed ID: 16861880
[TBL] [Abstract][Full Text] [Related]
23. Primary hepatic carcinoid and neuroendocrine carcinoma: clinicopathological and immunohistochemical study of five cases.
Pilichowska M; Kimura N; Ouchi A; Lin H; Mizuno Y; Nagura H
Pathol Int; 1999 Apr; 49(4):318-24. PubMed ID: 10365851
[TBL] [Abstract][Full Text] [Related]
24. [Four cases of primary neuroendocrine carcinoma in ear, nose, pharynx and larynx].
Feng Y; Xu G; Liu B; Wang H; Su X
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2003 Sep; 17(9):549-50. PubMed ID: 14658193
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements.
Steineck G; Reuter V; Kelly WK; Frank R; Schwartz L; Scher HI
Acta Oncol; 2002; 41(7-8):668-74. PubMed ID: 14651212
[TBL] [Abstract][Full Text] [Related]
26. [CT and MRI findings of primary hepatic neuroendocrine neoplasm].
Li JK; Wang M; Yuan J; Song ZG
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):600-606. PubMed ID: 28835083
[No Abstract] [Full Text] [Related]
27. Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms.
Brandi G; Paragona M; Campana D; Brighi N; Bondi A; Pantaleo MA; Corbelli J; Barbera MA; Biasco G
J Chemother; 2018 Feb; 30(1):53-58. PubMed ID: 28641483
[TBL] [Abstract][Full Text] [Related]
28. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
[TBL] [Abstract][Full Text] [Related]
29. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
[TBL] [Abstract][Full Text] [Related]
30. [Small cell neuroendocrine carcinoma of the bladder: A case report and review of the literature].
Chekrine T; De Bari B; Cassier P; Kulisa M; Chapet O; Mornex F
Cancer Radiother; 2011 Jun; 15(3):250-3. PubMed ID: 21420344
[TBL] [Abstract][Full Text] [Related]
31. Multimodality treatment for poorly differentiated neuroendocrine head and neck carcinomas--a single institution experience.
Görner M; Brasch F; Hirnle P; Gehl HB; Scholtz LU; Wegehenkel K; Sudhoff H
Eur J Cancer Care (Engl); 2013 Sep; 22(5):648-52. PubMed ID: 23701280
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
Caplin ME; Baudin E; Ferolla P; Filosso P; Garcia-Yuste M; Lim E; Oberg K; Pelosi G; Perren A; Rossi RE; Travis WD;
Ann Oncol; 2015 Aug; 26(8):1604-20. PubMed ID: 25646366
[TBL] [Abstract][Full Text] [Related]
33. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Wolin EM
Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas.
Liu DJ; Fu XL; Liu W; Zheng LY; Zhang JF; Huo YM; Li J; Hua R; Liu Q; Sun YW
World J Gastroenterol; 2017 Jan; 23(3):516-524. PubMed ID: 28210088
[TBL] [Abstract][Full Text] [Related]
35. Tumor of the liver (hepatocellular and high grade neuroendocrine carcinoma): a case report and review of the literature.
Garcia MT; Bejarano PA; Yssa M; Buitrago E; Livingstone A
Virchows Arch; 2006 Sep; 449(3):376-81. PubMed ID: 16896889
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series.
Imai H; Shirota H; Okita A; Komine K; Saijo K; Takahashi M; Takahashi S; Takahashi M; Shimodaira H; Ishioka C
Chemotherapy; 2016; 61(3):111-6. PubMed ID: 26636658
[TBL] [Abstract][Full Text] [Related]
37. Undifferentiated carcinoma of the liver with neuroendocrine features: a case report.
Nakasuka H; Okada S; Okusaka T; Ishii H; Ikeda M; Ito R; Kosakamoto H; Yoshimori M; Nakanishi Y; Sakamoto M
Jpn J Clin Oncol; 1998 Jun; 28(6):401-4. PubMed ID: 9730157
[TBL] [Abstract][Full Text] [Related]
38. [Conversion Therapy Using Etoposide and Cisplatin Chemotherapy for Liver Metastases from Advanced Gastric Mixed Adenoneuroendocrine Carcinoma - A Case Report].
Inaba Y; Fujita M; Ninomiya R; Hashimoto D
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1488-1490. PubMed ID: 29394677
[TBL] [Abstract][Full Text] [Related]
39. Thymic neuroendocrine carcinomas with combined features ranging from well-differentiated (carcinoid) to small cell carcinoma. A clinicopathologic and immunohistochemical study of 11 cases.
Moran CA; Suster S
Am J Clin Pathol; 2000 Mar; 113(3):345-50. PubMed ID: 10705813
[TBL] [Abstract][Full Text] [Related]
40. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
Hentic O; Hammel P; Couvelard A; Rebours V; Zappa M; Palazzo M; Maire F; Goujon G; Gillet A; Lévy P; Ruszniewski P
Endocr Relat Cancer; 2012 Dec; 19(6):751-7. PubMed ID: 22940375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
